000290167 001__ 290167
000290167 005__ 20250820121506.0
000290167 0247_ $$2doi$$a10.1016/S2468-1253(24)00091-8
000290167 0247_ $$2pmid$$apmid:38734024
000290167 0247_ $$2ISSN$$a2468-1253
000290167 0247_ $$2ISSN$$a2468-1156
000290167 0247_ $$2altmetric$$aaltmetric:163222634
000290167 037__ $$aDKFZ-2024-01003
000290167 041__ $$aEnglish
000290167 082__ $$a610
000290167 1001_ $$0P:(DE-He78)b1b2f6c878545eac4cbd9729d8c10b7d$$aWankhede, Durgesh$$b0$$eFirst author$$udkfz
000290167 245__ $$aClinical significance of combined tumour-infiltrating lymphocytes and microsatellite instability status in colorectal cancer: a systematic review and network meta-analysis.
000290167 260__ $$aLondon$$bElsevier$$c2024
000290167 3367_ $$2DRIVER$$aarticle
000290167 3367_ $$2DataCite$$aOutput Types/Journal article
000290167 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1721829541_14726
000290167 3367_ $$2BibTeX$$aARTICLE
000290167 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000290167 3367_ $$00$$2EndNote$$aJournal Article
000290167 500__ $$a#EA:C070#LA:C070# / 2024 Jul;9(7):609-619 / HI-TRON
000290167 520__ $$aMicrosatellite instability (MSI) status and tumour-infiltrating lymphocytes (TIL) are established prognostic factors in colorectal cancer. Previous studies evaluating the combination of TIL and MSI status identified distinct colorectal cancer subtypes with unique prognostic associations. However, these studies were often limited by sample size, particularly for MSI-high (MSI-H) tumours, and there is no comprehensive summary of the available evidence. We aimed to review the literature to compare the survival outcomes associated with the subtypes derived from the integrated MSI-TIL classification in patients with colorectal cancer.In this systematic review and network meta-analysis, we searched PubMed, Embase, Scopus, and the Cochrane Library without language restrictions, for articles published between Jan 1, 1990, and March 13, 2024. Patient cohorts comparing different combinations of TIL (high or low) and MSI status (MSI or microsatellite stable [MSS]) in patients with surgically resected colorectal cancer were included. Studies were excluded if they focused on neoadjuvant therapy or on other immune markers such as B cells or macrophages. Methodological quality assessment was done with the Newcastle-Ottawa scale; data appraisal and extraction was done independently by two reviewers. Summary estimates were extracted from published reports. The primary outcomes were overall survival, disease-free survival, and cancer-specific survival. A frequentist network meta-analysis was done to compare hazard ratios (HRs) and 95% CI for each outcome. The MSI-TIL subgroups were prognostically ranked based on P-score, bias, magnitude, and precision of associations with each outcome. The protocol is registered with PROSPERO (CRD42023461108).Of 302 studies initially identified, 21 studies (comprising 14 028 patients) were included in the systematic review and 19 (13 029 patients) in the meta-analysis. Nine studies were identified with a low risk of bias and the remaining ten had a moderate risk of bias. The MSI-TIL-high (MSI-TIL-H) subtype exhibited longer overall survival (HR 0·45, 95% CI 0·34-0·61; I2=77·7%), disease-free survival (0·43, 0·32-0·58; I2=61·6%), and cancer-specific survival (0·53, 0·43-0·66; I2=0%), followed by the MSS-TIL-H subtype for overall survival (HR 0·53, 0·41-0·69; I2=77·7%), disease-free survival (0·52, 0·41-0·64; I2=61·6%), and cancer-specific survival (0·55, 0·47-0·64; I2=0%) than did patients with MSS-TIL-low tumours (MSS-TIL-L). Patients with the MSI-TIL-L subtype had similar overall survival (0·88, 0·66-1·18; I2=77·7%) and disease-free survival (0·93, 0·69-1·26; I2=61·6%), but a modestly longer cancer-specific survival (0·72, 0·57-0·90; I2=0%) than did the MSS-TIL-L subtype. Results from the direct and indirect evidence were strongly congruous.The findings from this network meta-analysis suggest that better survival was only observed among patients with TIL-H colorectal cancer, regardless of MSI or MSS status. The integrated MSI-TIL classification should be further explored as a predictive tool for clinical decision-making in early-stage colorectal cancer.German Research Council (HO 5117/2-2).
000290167 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000290167 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000290167 7001_ $$0P:(DE-He78)b9e439a1aa1244925f92d547c0919349$$aYuan, Tanwei$$b1$$udkfz
000290167 7001_ $$0P:(DE-He78)028ee60cca729028708496826f077b58$$aKloor, Matthias$$b2$$udkfz
000290167 7001_ $$0P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aHalama, Niels$$b3$$udkfz
000290167 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4$$udkfz
000290167 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b5$$eLast author$$udkfz
000290167 773__ $$0PERI:(DE-600)2874542-5$$a10.1016/S2468-1253(24)00091-8$$gp. S2468125324000918$$n7$$p609-619$$tThe lancet / Gastroenterology & Hepatology$$v9$$x2468-1253$$y2024
000290167 8564_ $$uhttps://inrepo02.dkfz.de/record/290167/files/1-s2.0-S2468125324002280-main.pdf
000290167 8564_ $$uhttps://inrepo02.dkfz.de/record/290167/files/1-s2.0-S2468125324002280-main.pdf?subformat=pdfa$$xpdfa
000290167 8767_ $$8E-2024-00488-b$$92024-08-22$$d2024-12-27$$eHybrid-OA$$jZahlung erfolgt
000290167 909CO $$ooai:inrepo02.dkfz.de:290167$$popenCost$$pOpenAPC$$pVDB
000290167 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b1b2f6c878545eac4cbd9729d8c10b7d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000290167 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b9e439a1aa1244925f92d547c0919349$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000290167 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)028ee60cca729028708496826f077b58$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000290167 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000290167 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000290167 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000290167 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000290167 9141_ $$y2024
000290167 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET GASTROENTEROL : 2022$$d2023-08-24
000290167 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000290167 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000290167 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
000290167 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-24
000290167 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
000290167 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-24
000290167 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-24
000290167 915__ $$0StatID:(DE-HGF)9930$$2StatID$$aIF >= 30$$bLANCET GASTROENTEROL : 2022$$d2023-08-24
000290167 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000290167 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000290167 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
000290167 915pc $$0PC:(DE-HGF)0125$$2APC$$aDEAL: Elsevier 09/01/2023
000290167 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000290167 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000290167 9201_ $$0I:(DE-He78)D470-20160331$$kD470$$lKKE Angewandte Tumorbiologie$$x1
000290167 9201_ $$0I:(DE-He78)D196-20160331$$kD196$$lTranslationale Immuntherapie$$x2
000290167 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000290167 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000290167 980__ $$ajournal
000290167 980__ $$aVDB
000290167 980__ $$aI:(DE-He78)C070-20160331
000290167 980__ $$aI:(DE-He78)D470-20160331
000290167 980__ $$aI:(DE-He78)D196-20160331
000290167 980__ $$aI:(DE-He78)HD01-20160331
000290167 980__ $$aUNRESTRICTED
000290167 980__ $$aAPC